What is Codetta Biosciences?
Codetta Bio specializes in multi-omics technology for precision medicine, offering a platform that integrates the analysis of proteins, DNA, and RNA in a single workflow. Their flagship product, the Codetta Bio Concerto System, utilizes advanced techniques such as digital PCR and qPCR to deliver high-sensitivity and high-throughput biomarker measurements. The company targets various sectors including vaccine development, oncology, and gene therapy, aiming to redefine capabilities in translational research and clinical markets. With a focus on innovation and precision, Codetta Bio seeks to harmonize scientific data to facilitate breakthroughs in healthcare.
How much funding has Codetta Biosciences raised?
Codetta Biosciences has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2022): $15M with participation from Genoa Ventures, Vc23, and Anzu Partners
Key Investors in Codetta Biosciences
Genoa Ventures
Genoa Ventures is an investment firm focused on early-stage companies at the intersection of biology and technology, aiming to empower category-defining companies that can transform industries.
Vc23
VC23 Ventures is a life sciences-focused venture fund that invests in next-generation biotools, diagnostics, and analytical platforms, emphasizing collaboration and expertise to accelerate portfolio company growth.
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences, providing strategic support and business development expertise to accelerate growth.
What's next for Codetta Biosciences?
The recent major strategic investment positions Codetta Biosciences for accelerated growth and market penetration. This capital infusion is expected to fuel further development of their multi-omics platform and expand their reach within the oncology, vaccine development, and gene therapy markets. The company's focus on high-sensitivity biomarker measurement through its Concerto System suggests a strategic push towards enhancing translational research and clinical diagnostics, potentially leading to new partnerships and broader adoption of their technology in the precision medicine landscape.
See full Codetta Biosciences company page
